ArticleNucleic acids research2003
RNA cleaving '10-23' DNAzymes with enhanced stability and activity.
Article in Nucleic acids research, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed.
- Chemically Evolved XNAzyme Platforms for Effective In Vivo Gene Regulation.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Chemical Modification Strategies for Therapeutic Oligonucleotides: Mechanism Compatibility, Design Trade-Offs, and Translational Barriers.Molecules (Basel, Switzerland) · 2026Review
- Dual-functional nanoplatform for simultaneous degradation of circRNAJournal of Zhejiang University. Science. B · 2026Article
- Mapping the Structure and Conformational Landscape of the 10-23 DNAzyme.ACS chemical biology · 2026Article
- The 10-23 DNAzyme in Biosensing and Diagnostics: Applications, Challenges, and Future Directions.Angewandte Chemie (International ed. in English) · 2026Review
- Chemically Modified DNAzyme with Enhanced Activity for Sensitive MicroRNA Imaging in Live Cells.Molecules (Basel, Switzerland) · 2026Article
- Advances in DNAzyme Selection, Molecular Engineering and Biomedical Applications.International journal of molecular sciences · 2026Review
- A modified X10-23 DNAzyme that can better access large, structured RNA targets.Nucleic acids research · 2026Article
- Allele-specific knockdown by an engineered DNAzyme capable of RNase H1 evasion.Nucleic acids research · 2026Article
- Dual-Site Chemically Engineered MNAzymes for One-Pot Isothermal Detection of MicroRNAs.ACS omega · 2025Article
- Hydrogel Conjugation: Engineering of Hydrogels for Drug Delivery.Pharmaceutics · 2025Review
- Directed assembly of single-stranded DNA fragments for data storage via protein-free catalytic splint ligation.Nucleic acids research · 2025Article
- Facilitating DNAzyme transport across the blood-brain barrier with nanoliposome technology.Scientific reports · 2025Article
- An epimer of threose nucleic acid enhances oligonucleotide exonuclease resistance through end capping.Communications chemistry · 2025Article
- Influence of LNA modifications on the activity of the 10-23 DNAzyme.RSC advances · 2025Article
- Opening new frontiers with catalytic nucleic acids in miRNA inhibition.Frontiers in pharmacology · 2025Review
- Growing functional artificial cytoskeletons in the viscoelastic confinement of DNA synthetic cells.Nature chemical engineering · 2025Article
- Bioactive Self-Assembled Nanoregulator Enhances Hematoma Resolution and Inhibits Neuroinflammation in the Treatment of Intracerebral Hemorrhage.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Trinucleotide cap analogs with triphosphate chain modifications: synthesis, properties, and evaluation as mRNA capping reagents.Nucleic acids research · 2024Article
- Making target sites in large structured RNAs accessible to RNA-cleaving DNAzymes through hybridization with synthetic DNA oligonucleotides.Nucleic acids research · 2024Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
'10-23' DNAzymes can be used to cleave any target RNA in a sequence-specific manner. For applications in vivo, they have to be stabilised against nucleolytic attack by the introduction of modified nucleotides without obstructing cleavage activity. In this study, we optimise the design of a DNAzyme targeting the 5'-non-translated region of the human rhinovirus 14, a common cold virus, with regard to its kinetic properties and its stability against nucleases. We compare a large number of DNAzymes against the same target site that are stabilised by the use of a 3'-3'-inverted thymidine, phosphorothioate linkages, 2'-O-methyl RNA and locked nucleic acids, respectively. Both cleavage activity and nuclease stability were significantly enhanced by optimisation of arm length and content of modified nucleotides. Furthermore, we introduced modified nucleotides into the catalytic core to enhance stability against endonucleolytic degradation without abolishing catalytic activity. Our findings enabled us to establish a design for DNAzymes containing nucleotide modifications both in the binding arms and in the catalytic core, yielding a species with up to 10-fold enhanced activity and significantly elevated stability against nucleolytic cleavage. When transferring the design to a DNAzyme against a different target, only a slight modification was necessary to retain activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.